ライフサイエンスコーパス: antibody-dependent

1 in receptor (CD11b DTR) transgenic mice, and antibody-dependent ablation of CCR2(hi) monocytes.

2 (89)Zr-alphaGPC3 demonstrated antibody-dependent, antigen-specific tumor binding.

3 Antibody-dependent bacterial targeting specifies the inf

4 en (zonadhesin), and develop CD4 T-cell- and antibody-dependent bilateral autoimmune orchitis.

5 s and heterologous virus neutralization, and antibody-dependent cell cytotoxicity (ADCC) responses we

6 ulate the rate of target cell destruction in antibody-dependent cell cytotoxicity (ADCC).

7 IPH4102 antitumor activity was mediated by antibody-dependent cell cytotoxicity and phagocytosis.

8 activity, anti-CMV IgG, and NK cell-mediated antibody-dependent cell cytotoxicity were present in ale

9 as prominent effector cells and induction of antibody-dependent cell phagocytosis as one of the prima

10 the immunologic synapse and potently induce antibody-dependent cell-mediated antiviral responses: (i

11 ngagement and provide them with an intrinsic antibody-dependent cell-mediated cytotoxic (ADCC) potent

12 d with their parental forms, potent in vitro antibody-dependent cell-mediated cytotoxicity (0.1-0.3 m

13 FcgammaRIIIa binding and function, including antibody-dependent cell-mediated cytotoxicity (ADCC) act

14 histochemistry, for affinity by BIACORE, for antibody-dependent cell-mediated cytotoxicity (ADCC) and

15 ental insights into the relationship between antibody-dependent cell-mediated cytotoxicity (ADCC) and

16 uring the killing of virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC) are

17 to ipilimumab by multicolor flow cytometry, antibody-dependent cell-mediated cytotoxicity (ADCC) ass

18 Moreover, antibody-dependent cell-mediated cytotoxicity (ADCC) ass

19 Results from serum transfer experiments and antibody-dependent cell-mediated cytotoxicity (ADCC) ass

20 Antibody-dependent cell-mediated cytotoxicity (ADCC) by

21 evels of indirect tumor cell killing such as antibody-dependent cell-mediated cytotoxicity (ADCC) by

22 Antibody-dependent cell-mediated cytotoxicity (ADCC) by

23 es that enhance tumor cell susceptibility to antibody-dependent cell-mediated cytotoxicity (ADCC) by

24 but their potential for cancer treatment via antibody-dependent cell-mediated cytotoxicity (ADCC) has

25 ils cultured from mouse bone marrow produced antibody-dependent cell-mediated cytotoxicity (ADCC) in

26 novicida DeltafopC immune serum, suggesting antibody-dependent cell-mediated cytotoxicity (ADCC) in

27 odies and explains how they achieve a higher antibody-dependent cell-mediated cytotoxicity (ADCC) pot

28 rent study, we evaluated the kinetics of the antibody-dependent cell-mediated cytotoxicity (ADCC) res

29 ion, downregulate HER3, and mediate enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) via

30 oma activity by spontaneous cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) whe

31 the susceptibility of HIV-infected cells to antibody-dependent cell-mediated cytotoxicity (ADCC), an

32 effector functions of antibodies, including antibody-dependent cell-mediated cytotoxicity (ADCC), in

33 asure the killing of virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC), we

34 Antibody-dependent cell-mediated cytotoxicity (ADCC), wh

35 effectively targeted CML LSPCs by selective antibody-dependent cell-mediated cytotoxicity (ADCC)-fac

36 ured by glycans that either promote or block antibody-dependent cell-mediated cytotoxicity (ADCC).

37 ability to eliminate virus-infected cells by antibody-dependent cell-mediated cytotoxicity (ADCC).

38 unctions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC).

39 their surface are preferentially targeted by antibody-dependent cell-mediated cytotoxicity (ADCC).

40 complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).

41 rum including pseudovirus neutralization and antibody-dependent cell-mediated cytotoxicity (ADCC).

42 urface can be bound by antibodies to mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

43 enhanced virus replication and resistance to antibody-dependent cell-mediated cytotoxicity (ADCC).

44 ic antibodies, arising in part from enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).

45 cy by palivizumab in the cotton rat and that antibody-dependent cell-mediated cytotoxicity activity c

46 as glycoengineered, which resulted in strong antibody-dependent cell-mediated cytotoxicity activity.

47 es, and generation of antibodies with potent antibody-dependent cell-mediated cytotoxicity activity.

48 The antibody-dependent cell-mediated cytotoxicity and apopto

49 (hYP7 and hYP9.1b) in the IgG format induced antibody-dependent cell-mediated cytotoxicity and comple

50 The lack of effector functions, such as antibody-dependent cell-mediated cytotoxicity and comple

51 anti-neuraminidase antibodies weakly induced antibody-dependent cell-mediated cytotoxicity and enhanc

52 binding, neuraminidase inhibition, in vitro antibody-dependent cell-mediated cytotoxicity and in viv

53 Despite this, reverse antibody-dependent cell-mediated cytotoxicity assays sho

54 feron gamma production, resulting in greater antibody-dependent cell-mediated cytotoxicity compared w

55 In addition, SEFL variants demonstrated no antibody-dependent cell-mediated cytotoxicity in vitro a

56 odies displayed cellular phagocytosis and/or antibody-dependent cell-mediated cytotoxicity in vitro O

57 outbreak variants of Ebola virus and mediate antibody-dependent cell-mediated cytotoxicity in vitro.

58 ch combines potent signaling inhibition with antibody-dependent cell-mediated cytotoxicity induction

59 ying specificities regulate the magnitude of antibody-dependent cell-mediated cytotoxicity induction.

60 ging Microscopy in Nanowell Grids to analyze antibody-dependent cell-mediated cytotoxicity kinetics o

61 In contrast, antibody-dependent cell-mediated cytotoxicity produced b

62 reactive antibodies were capable of inducing antibody-dependent cell-mediated cytotoxicity to autolog

63 hu14.18 has been shown to elicit a level of antibody-dependent cell-mediated cytotoxicity toward hum

64 chanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antib

65 TF:FVIIa-dependent intracellular signaling, antibody-dependent cell-mediated cytotoxicity, and rapid

66 d optimized structure for the enhancement of antibody-dependent cell-mediated cytotoxicity, complemen

67 D16-dependent degranulation pathway, but not antibody-dependent cell-mediated cytotoxicity, contribut

68 receptor alpha that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patie

69 ween milk or plasma neutralization activity, antibody-dependent cell-mediated cytotoxicity, or HIV-1

70 ticular the IgG1 and IgG3 subclass mediating antibody-dependent cell-mediated cytotoxicity, seem to p

71 role in patients undergoing mAb therapy via antibody-dependent cell-mediated cytotoxicity, thus expl

72 and engagement of myeloid effector cells for antibody-dependent cell-mediated cytotoxicity, were simi

73 of NMO patient serum reduced by >95% CDC and antibody-dependent cell-mediated cytotoxicity, without i

74 ased in vivo tumor cell clearance, NKG2D- or antibody-dependent cell-mediated cytotoxicity-induced tu

75 5 receptor alpha, inducing apoptosis through antibody-dependent cell-mediated cytotoxicity.

76 ing primarily unlicensed NK cells to mediate antibody-dependent cell-mediated cytotoxicity.

77 y, which promotes NK cell activation through antibody-dependent cell-mediated cytotoxicity.

78 On NK cells, 4-1BB signaling can increase antibody-dependent cell-mediated cytotoxicity.

79 N9 virus through mechanisms likely involving antibody-dependent cell-mediated cytotoxicity.

80 odies were poor inducers and did not inhibit antibody-dependent cell-mediated cytotoxicity.

81 Antibody-dependent cell-mediated phagocytosis (ADCP) was

82 Antibody-dependent cell-mediated phagocytosis, virus inh

83 Antibody-dependent cell-mediated viral inhibition (ADCVI

84 ular cytotoxicity (ADCC) titers, and percent antibody-dependent cell-mediated viral inhibition.

85 ent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI

86 for Fcgamma receptor and variant function in antibody-dependent cell-mediated virus inhibition (ADCVI

87 The mAbs were evaluated functionally by antibody-dependent, cell-mediated cytotoxicity (ADCC) an

88 l blood mononuclear cell assay, and moderate antibody-dependent, cell-mediated cytotoxicity activity

89 d followed by isotype switching for improved antibody-dependent, cell-mediated cytotoxicity activity.

90 and fixation as well as Fc-gamma-dependent, antibody-dependent, cell-mediated cytotoxity in both mur

91 de FcgammaR signals to stimulate or suppress antibody-dependent, cell-mediated depletion of antigen-b

92 versely affect the ability of mAbs to induce antibody dependent cellular cytotoxicity (ADCC).

93 XmAb5592 also augmented antibody dependent cellular phagocytosis (ADCP) by macro

94 ecificity) and effector function activities (antibody dependent cellular phagocytosis, cellular cytot

95 lobulin G1 antibody variant with compromised antibody-dependent cellular cytotoxicity (ADCC) activity

96 ust cross-clade binding and neutralizing and antibody-dependent cellular cytotoxicity (ADCC) activity

97 ngly, the presence of antibodies with potent antibody-dependent cellular cytotoxicity (ADCC) activity

98 antibodies (Abs), those capable of mediating antibody-dependent cellular cytotoxicity (ADCC) activity

99 (Abs) to the V1V2 region of gp120 with high antibody-dependent cellular cytotoxicity (ADCC) activity

100 and that this protection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity

101 The ALVAC/AIDSVax vaccine induced antibody-dependent cellular cytotoxicity (ADCC) against

102 The antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

103 Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

104 ility to opsonize viral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against

105 b) directs natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against

106 iminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and anti

107 These Treg suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and thei

108 To investigate antibody-dependent cellular cytotoxicity (ADCC) as a con

109 phagocytosis, NK cell activation assays, and antibody-dependent cellular cytotoxicity (ADCC) assays.

110 Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggre

111 ycan fucosylation have been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allow

112 g antibodies with effector functions such as antibody-dependent cellular cytotoxicity (ADCC) contribu

113 oss-reactive antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) effector

114 ible (CDi) neutralizing epitopes targeted by antibody-dependent cellular cytotoxicity (ADCC) effector

115 onses at an early time point correlated with antibody-dependent cellular cytotoxicity (ADCC) function

116 virus type 1 (HIV-1) Env and able to mediate antibody-dependent cellular cytotoxicity (ADCC) have bee

117 ng evidence supports a role for HIV-specific antibody-dependent cellular cytotoxicity (ADCC) in contr

118 -HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversel

119 Antibody-dependent cellular cytotoxicity (ADCC) is media

120 Antibody-dependent cellular cytotoxicity (ADCC) may be a

121 Therefore, antibody-dependent cellular cytotoxicity (ADCC) may play

122 Nonneutralizing antibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may prov

123 Elimination of HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) requires

124 levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) response

125 itopes) as targets of potentially protective antibody-dependent cellular cytotoxicity (ADCC) response

126 ding IgG and IgA as well as neutralizing and antibody-dependent cellular cytotoxicity (ADCC) response

127 XmAb5592 increased antibody-dependent cellular cytotoxicity (ADCC) several

128 complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through

129 ith prechallenge serum antienvelope avidity, antibody-dependent cellular cytotoxicity (ADCC) titers,

130 There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to elimi

131 e HIV-1 reservoir.IMPORTANCE Mobilization of antibody-dependent cellular cytotoxicity (ADCC) to elimi

132 protein expressed by infected cells mobilize antibody-dependent cellular cytotoxicity (ADCC) to elimi

133 In the secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was anot

134 tes biological effector functions, including antibody-dependent cellular cytotoxicity (ADCC) which is

135 ating the factors that modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will hel

136 Complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apo

137 e breadth of HIV-1 gp120 and V1V2 responses, antibody-dependent cellular cytotoxicity (ADCC), and low

138 The MAbs mediated antibody-dependent cellular cytotoxicity (ADCC), and mic

139 Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and mod

140 b triggers natural killer (NK)-cell-mediated antibody-dependent cellular cytotoxicity (ADCC), but lit

141 functions, including tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infecte

142 cts on virus infectivity, antibodies mediate antibody-dependent cellular cytotoxicity (ADCC), the kil

143 ese epitopes and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC), we trea

144 e, core fucosylation significantly decreases antibody-dependent cellular cytotoxicity (ADCC), whereas

145 One such mechanism is antibody-dependent cellular cytotoxicity (ADCC), whereby

146 Fc N-glycans leads to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while t

147 Cross-reactive influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activati

148 ed that human natural killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mec

149 tion with either lineage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediatin

150 d rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC).

151 dividuals contain antibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC).

152 inate cells reactivated from latency through antibody-dependent cellular cytotoxicity (ADCC).

153 lso kills MET-overexpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC).

154 ve demonstrated that CD4i antibodies mediate antibody-dependent cellular cytotoxicity (ADCC).

155 d NK cell degranulation and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

156 of tumour-infiltrating regulatory T cells by antibody-dependent cellular cytotoxicity (ADCC).

157 ugh Fc receptor-dependent processes, such as antibody-dependent cellular cytotoxicity (ADCC).

158 xtensively studied for its role in mediating antibody-dependent cellular cytotoxicity (ADCC).

159 tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC).

160 es, possibly owing to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).

161 ncreases susceptibility of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

162 (NK)-cell degranulation and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

163 s, of which the major mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzuma

164 infected cells by natural killer (NK) cells (antibody-dependent cellular cytotoxicity [ADCC]) or comp

165 te fucose-deficient antibodies with enhanced antibody-dependent cellular cytotoxicity activities.

166 g to FcgammaRIIIA and thereby decreasing the antibody-dependent cellular cytotoxicity activities.

167 No alteration in gamma-receptor binding and antibody-dependent cellular cytotoxicity activity was ob

168 by generation of reactive oxygen species or antibody-dependent cellular cytotoxicity activity, but l

169 cking core N-glycan residues mediated higher antibody-dependent cellular cytotoxicity against human t

170 An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+H

171 fic CD16(pos) gammadelta T cells can perform antibody-dependent cellular cytotoxicity against stromal

172 ti-IL1RAP antibody capable of both achieving antibody-dependent cellular cytotoxicity and blocking of

173 pecific monoclonal antibodies display robust antibody-dependent cellular cytotoxicity and CD4-depende

174 The antibody-dependent cellular cytotoxicity and complement-

175 tes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-

176 f a CD20-targeting antibody had no impact on antibody-dependent cellular cytotoxicity and did not cha

177 emistry, and a target for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo eli

178 redicted susceptibility to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred in

179 tes immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosi

180 odification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically r

181 ivation of the classical complement pathway, antibody-dependent cellular cytotoxicity by innate immun

182 he asymmetrically engineered Fc variants for antibody-dependent cellular cytotoxicity enhancement cou

183 Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity involving Fcgam

184 Our study highlights the potential role that antibody-dependent cellular cytotoxicity might play in a

185 dy inhibits cell growth and induces in vitro antibody-dependent cellular cytotoxicity of human neurob

186 ne neutralization of RANKL with induction of antibody-dependent cellular cytotoxicity of natural kill

187 mulation, by the use of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKI

188 NSCC sensitivity in a manner associated with antibody-dependent cellular cytotoxicity rather than EGF

189 levels of IgA antibodies, and high levels of antibody-dependent cellular cytotoxicity responses and H

190 In each study, protection correlated with antibody-dependent cellular cytotoxicity specific for CD

191 ed in N. benthamiana are capable of inducing antibody-dependent cellular cytotoxicity, an activity no

192 both macrophage-dependent FcgammaR-mediated antibody-dependent cellular cytotoxicity, and by direct

193 le mechanisms including apoptosis induction, antibody-dependent cellular cytotoxicity, antibody-depen

194 including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-depen

195 2M activates natural killer cells to enhance antibody-dependent cellular cytotoxicity, mediates compl

196 d functional activity (virus neutralization, antibody-dependent cellular cytotoxicity, phagocytosis,

197 f natural killer cells, the key mediators of antibody-dependent cellular cytotoxicity, to human AMR i

198 biting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests

199 ) arm that was derived from broadly binding, antibody-dependent cellular cytotoxicity-mediating antib

200 highest titers of binding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antib

201 ecific MAbs that showed Galcer blocking, the antibody-dependent cellular cytotoxicity-mediating CH38

202 elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity.

203 enhancing NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.

204 ediated by donor-specific antibodies through antibody-dependent cellular cytotoxicity.

205 us virion capture, virus neutralization, and antibody-dependent cellular cytotoxicity.

206 get IL-5R and attenuate eosinophilia through antibody-dependent cellular cytotoxicity.

207 th IgG Fc-mediated complement activation and antibody-dependent cellular cytotoxicity.

208 ors via complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.

209 ody for easy-to-neutralize SIV isolates, and antibody-dependent cellular cytotoxicity.

210 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

211 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

212 -induced (CD4i) antibodies capable of potent antibody-dependent cellular cytotoxicity.

213 bs, readily induced by vaccines, can trigger antibody-dependent cellular effector functions, through

214 ived from MSP3 as the strongest predictor of antibody-dependent cellular inhibition.

215 ed functional activities, including ADCC and antibody-dependent cellular phagocytosis (ADCP) activiti

216 ve antitumor antibody responses by enhancing antibody-dependent cellular phagocytosis (ADCP) in xenog

217 xenografts by enhancing macrophage-mediated antibody-dependent cellular phagocytosis (ADCP), but syn

218 However, there was little change in the antibody-dependent cellular phagocytosis activity.

219 6M0-mcMMAF recruits macrophages and mediates antibody-dependent cellular phagocytosis of MM cells.

220 dy-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apo

221 n, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement

222 y, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, programmed cel

223 to avidly capture HIV virions and to mediate antibody-dependent cellular phagocytosis, suggesting a r

224 vo, namely antibody-induced inflammation and antibody-dependent cellular phagocytosis.

225 their surface are preferentially targeted by antibody-dependent cellular-mediated cytotoxicity (ADCC)

226 I antibodies of various isotypes in ADCC and antibody-dependent cellular-phagocytosis (ADCP) assays.

227 ell surface, thereby reducing recognition by antibody-dependent clearance by natural killer cells.

228 ere form of rejection, mediated primarily by antibody-dependent complement (C) activation.

229 Activation of antibody-dependent complement pathways mediated tissue i

230 ng capacity) and has increased resistance to antibody-dependent complement-mediated killing compared

231 ansferase that is required for resistance to antibody-dependent complement-mediated killing in a muri

232 ndings indicate that increased resistance to antibody-dependent complement-mediated killing secondary

233 ors of complement activation (RCA) to resist antibody-dependent complement-mediated lysis (ADCML).

234 eir viral envelopes and, as a result, escape antibody-dependent complement-mediated lysis (ADCML).

235 quality and the quantity of NK cell-mediated antibody-dependent cytotoxicity by endowing more NK cell

236 ation activity limited to tier 1 viruses and antibody-dependent cytotoxicity responses (ADCC) after D

237 cells with tumor cells, which can result in antibody-dependent cytotoxicity.

238 ding, neutralized H5N1 viruses, and mediated antibody-dependent effector activity.

239 v antigen engagement which lead to effective antibody-dependent effector function directed to the non

240 s provide additional evidence that effective antibody-dependent effector function in the cluster A re

241 ad compound against all 4 serotypes of DENV, antibody-dependent enhanced (ADE) infection, and ex vivo

242 Neutralization and antibody-dependent enhanced replication experiments show

243 lusion, here we find that in the presence of Antibody Dependent Enhancement (ADE) heterogeneity can i

244 ion showed significant capacity for in vitro antibody dependent enhancement of Dengue-1, 2, 3 and 4 s

245 evere dengue disease focus on the process of antibody-dependent enhancement (ADE) as a primary risk f

246 The proposed antibody-dependent enhancement (ADE) mechanism for sever

247 tate Zika virus (ZIKV) infection through the antibody-dependent enhancement (ADE) mechanism.

248 Antibody-dependent enhancement (ADE) of dengue virus (DE

249 protection against DENV disease and prevents antibody-dependent enhancement (ADE) of disease in mice.

250 mmune serum, it has been shown in vitro that antibody-dependent enhancement (ADE) of ZIKV infection c

251 ble of both cross-neutralization, as well as antibody-dependent enhancement (ADE) of ZIKV infection.

252 cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection.

253 Moreover, antibody-dependent enhancement (ADE) was not observed ag

254 e virus (DENV) infections is associated with antibody-dependent enhancement (ADE), and it was recentl

255 eutralization potency, enhanced infection by antibody-dependent enhancement (ADE).

256 e-infection, mainly because of the effect of antibody-dependent enhancement (ADE).

257 This phenomenon is referred to as antibody-dependent enhancement (ADE).

258 Progression to DHF/DSS is attributed to antibody-dependent enhancement (ADE); however, because o

259 tions in flavivirus immune vaccinees such as Antibody-Dependent Enhancement (ADE, a phenomenon involv

260 ovide statistical support for the process of antibody-dependent enhancement (but not original antigen

261 ve broad HA reactivity, yet they do not have antibody-dependent enhancement activity.

262 Antibody-dependent enhancement has been implicated in mo

263 Among the 4 serotypes of dengue virus, antibody-dependent enhancement is thought to enhance vir

264 Antibody-dependent enhancement may explain the severe di

265 In contrast, antibody-dependent enhancement of bacterial infection is

266 I agonist blocked both primary infection and antibody-dependent enhancement of DENV infection.

267 -gamma receptor (FcgammaR), a process termed antibody-dependent enhancement of DENV infection.

268 ted against DENV-2 by using a mouse model of antibody-dependent enhancement of infection (ADE)-induce

269 This process has been termed antibody-dependent enhancement of infection and has sign

270 zed all four serotypes of DENV, and mediated antibody-dependent enhancement of infection in Fc recept

271 These results suggest that antibody-dependent enhancement of NK activity may yield

272 n in late infancy is a direct consequence of antibody-dependent enhancement of replication.

273 Although suspected, such antibody-dependent enhancement of severe disease has not

274 nd vice versa because of a phenomenon termed antibody-dependent enhancement.

275 igenetic modification of gene expression and antibody-dependent expansion.

276 mma-deficient NK cells that display enhanced antibody-dependent functional activity.

277 st closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited

278 It is now conceivable that an antibody-dependent HIV vaccine might be possible, given

279 osolic immunoglobulin receptor that mediates antibody-dependent intracellular neutralization (ADIN).

280 ly induced lymphoma Gal-1 expression ablated antibody-dependent lymphoma phagocytosis in vitro and ly

281 ibits subsequent S. aureus acquisition in an antibody-dependent manner and elicits antibody that cros

282 fected cells (both HCMV and influenza) in an antibody-dependent manner.

283 hils (PPNs) killed chlamydiae in vitro in an antibody-dependent manner.

284 pandemic H1N1 influenza virus isolate in an antibody-dependent manner.

285 Antibody-dependent mast cell activation constitutes a no

286 ovide epidemiological evidence that multiple antibody-dependent mechanisms contribute to protective i

287 Pathological and clinical studies implicate antibody-dependent mechanisms in the immunopathogenesis

288 primary lymphoma cells through monocyte- and antibody-dependent mechanisms, we found that lymphoma de

289 SEFL mutations eliminated off-target antibody-dependent monocyte phagocytosis of cynomolgus m

290 of FcgammaR function dramatically inhibited antibody-dependent murine ITP and successfully circumven

291 Antibody-dependent neutralization of secreted DDT exacer

292 Enhanced levels of CD16 expression and antibody-dependent NK cell cytotoxic function of HT reci

293 to the production of class-switched anti-MOG antibodies, dependent on the presence of hemagglutinin-s

294 ed binding antibody against scaffolded V1V2, antibody-dependent phagocytic activity against VLP-coate

295 y-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear.

296 Using intravital microscopy, we found that antibody-dependent phagocytosis (ADPh) by macrophages is

297 In this study, we investigated antibody-dependent phagocytosis of HIV immune complexes,

298 ransplanted organs and is often viewed as an antibody-dependent process.

299 Here we optimize the antibody-dependent respiratory burst (ADRB) assay, which

300 urvival, suggesting antibody-independent and antibody-dependent roles for B cells in the outcome to s